Taking Stock of the Evolving Treatment Landscape for Acute GvHD in HSCT: Proceedings from a Clinical Olympics℠

Program Overview

Allogeneic hematopoietic cell transplantation is a potentially curative therapy for many malignant and nonmalignant hematologic diseases. Acute graft-versus-host disease (aGVHD) is a common complication associated with this procedure that can affect up to 50% of patients. Patients with aGVHD commonly present with a maculopapular rash, nausea, vomiting, profuse watery diarrhea and abdominal cramping, and hyperbilirubinemia with jaundice. In this educational activity, renowned GVHD experts discuss staging/grading of GVHD, current prophylactic and treatment strategies, and emerging agents.

1.00 CE Credit(s)

Expires: January 31, 2024

Target Audience

Hematology, hematology/oncology, and transplantation clinicians

Educational Objectives

Upon completion of this activity, participants should be better able to:

Apply available therapies and guidelines for acute graft-versus-host disease (aGVHD) management in hematopoietic stem cell transplantation (HSCT) patients
Examine current data and ongoing clinical trials of emerging therapies for the management of acute GVHD in the allogeneic HSCT population

Activity Faculty

Miguel-Angel Perales, MD

Chief, Adult Bone Marrow Transplantation Service
Memorial Sloan Kettering Cancer Center
Associate Professor, Medicine
Weill Cornell Medical College
New York, NY

Nelson J. Chao, MD, MBA

Donald D. and Elizabeth G. Cooke Professor
Chief, Division of Hematologic Malignancies and Cellular Therapy/BMT
Director, Global Cancer
Duke University
Durham, NC

Sung Won Choi, MD, MS

Professor, Pediatrics
Hematology/Oncology
Edith S Briskin and Shirley K Schlafer Research Professor
Blood and Marrow Transplantation Program
University of Michigan
Ann Arbor, MI

Provider Statement

This activity is provided by RMEI Medical Education, LLC

Supporter Statement

This activity is supported by an independent educational grant from CSL Behring LLC.

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications. The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Disclaimer Statement

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities. 